{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T00:22:48Z","timestamp":1792801368245,"version":"4.5.0"},"reference-count":56,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T00:00:00Z","timestamp":1709251200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T00:00:00Z","timestamp":1709251200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T00:00:00Z","timestamp":1709251200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T00:00:00Z","timestamp":1709251200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T00:00:00Z","timestamp":1709251200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T00:00:00Z","timestamp":1709251200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T00:00:00Z","timestamp":1709251200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100002842","name":"Chiang Mai University","doi-asserted-by":"publisher","award":["RG 38\/2566"],"award-info":[{"award-number":["RG 38\/2566"]}],"id":[{"id":"10.13039\/501100002842","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["General Hospital Psychiatry"],"published-print":{"date-parts":[[2024,3]]},"DOI":"10.1016\/j.genhosppsych.2024.02.008","type":"journal-article","created":{"date-parts":[[2024,2,19]],"date-time":"2024-02-19T11:24:00Z","timestamp":1708341840000},"page":"124-133","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":23,"special_numbering":"C","title":["Second-generation antipsychotics for Parkinson's disease psychosis: A systematic review and network meta-analysis"],"prefix":"10.1016","volume":"87","author":[{"given":"Manit","family":"Srisurapanont","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chawisa","family":"Suradom","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sirijit","family":"Suttajit","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Subsai","family":"Kongsaengdao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benchalak","family":"Maneeton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.genhosppsych.2024.02.008_bb0005","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1155\/2013\/645429","article-title":"Parkinson disease psychosis: update","volume":"27","author":"Friedman","year":"2013","journal-title":"Behav Neurol"},{"key":"10.1016\/j.genhosppsych.2024.02.008_bb0010","doi-asserted-by":"crossref","first-page":"1319","DOI":"10.3233\/JPD-213035","article-title":"Incidence, prevalence, and mortality of psychosis associated with Parkinson\u2019s disease (1991-2010)","volume":"12","author":"Stang","year":"2022","journal-title":"J Parkinsons Dis"},{"key":"10.1016\/j.genhosppsych.2024.02.008_bb0015","first-page":"7","article-title":"Parkinson\u2019s disease psychosis: presentation, diagnosis and management","author":"Schneider","year":"2017","journal-title":"Neurodegener Dis Manag"},{"key":"10.1016\/j.genhosppsych.2024.02.008_bb0020","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1177\/08919887211018280","article-title":"Psychosis in Parkinson\u2019s disease: current treatment options and impact on patients and caregivers","volume":"34","author":"Segal","year":"2021","journal-title":"J Geriatr Psychiatry Neurol"},{"key":"10.1016\/j.genhosppsych.2024.02.008_bb0025","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1177\/0269881113478281","article-title":"Comparison of the anti-dopamine D\u2082 and anti-serotonin 5-HT(2A) activities of chlorpromazine, bromperidol, haloperidol and second-generation antipsychotics parent compounds and metabolites thereof","volume":"27","author":"Suzuki","year":"2013","journal-title":"J Psychopharmacol (Oxford, England)"},{"key":"10.1016\/j.genhosppsych.2024.02.008_bb0030","doi-asserted-by":"crossref","first-page":"1411","DOI":"10.1007\/s00406-021-01335-y","article-title":"Should \u201ctypical\u201d, first-generation antipsychotics no longer be generally used in the treatment of schizophrenia?","volume":"271","author":"Leucht","year":"2021","journal-title":"Eur Arch Psychiatry Clin Neurosci"},{"key":"10.1016\/j.genhosppsych.2024.02.008_bb0035","first-page":"46","article-title":"Pimavanserin in the treatment of Parkinson\u2019s disease psychosis: meta-analysis and meta-regression of randomized clinical trials","volume":"19","author":"Mansuri","year":"2022","journal-title":"Innov Clin Neurosci"},{"key":"10.1016\/j.genhosppsych.2024.02.008_bb0040","first-page":"78","article-title":"Efficacy and safety of atypical antipsychotics for psychosis in Parkinson\u2019s disease: a systematic review and Bayesian network meta-analysis","author":"Iketani","year":"2020","journal-title":"Parkinsonism Relat Disord"},{"key":"10.1016\/j.genhosppsych.2024.02.008_bb0045","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1177\/08919887231154933","article-title":"Comparative efficacy, safety, and acceptability of pimavanserin and other atypical antipsychotics for Parkinson\u2019s disease psychosis: systematic review and network meta-analysis","volume":"36","author":"Yunusa","year":"2023","journal-title":"J Geriatr Psychiatry Neurol"},{"key":"10.1016\/j.genhosppsych.2024.02.008_bb0050","doi-asserted-by":"crossref","first-page":"2137","DOI":"10.2147\/NDT.S201029","article-title":"Atypical antipsychotics for Parkinson\u2019s disease psychosis: a systematic review and meta-analysis","volume":"15","author":"Zhang","year":"2019","journal-title":"Neuropsychiatr Dis Treat"},{"key":"10.1016\/j.genhosppsych.2024.02.008_bb0055","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1007\/s10742-016-0155-7","article-title":"Combining non-randomized and randomized data in clinical trials using commensurate priors","volume":"16","author":"Zhao","year":"2016","journal-title":"Health Serv Outcomes Res Methodol"},{"key":"10.1016\/j.genhosppsych.2024.02.008_bb0060","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"372","author":"Page","year":"2021","journal-title":"BMJ"},{"key":"10.1016\/j.genhosppsych.2024.02.008_bb0065","series-title":"Cochrane handbook for systematic reviews of interventions","author":"Higgins","year":"2019"},{"key":"10.1016\/j.genhosppsych.2024.02.008_bb0070","series-title":"MKinfer: inferential statistics (version 1.1)","author":"Matthias","year":"2023"},{"key":"10.1016\/j.genhosppsych.2024.02.008_bb0075","article-title":"RoB 2: a revised tool for assessing risk of bias in randomised trials","volume":"366","author":"Sterne","year":"2019","journal-title":"BMJ"},{"key":"10.1016\/j.genhosppsych.2024.02.008_bb0080","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1037\/0033-2909.112.1.155","article-title":"A power primer","volume":"112","author":"Cohen","year":"1992","journal-title":"Psychol Bull"},{"key":"10.1016\/j.genhosppsych.2024.02.008_bb0085","series-title":"R: a language and environment for statistical computing","author":"R Core Team","year":"2023"},{"key":"10.1016\/j.genhosppsych.2024.02.008_bb0090","series-title":"Netmeta: network meta-analysis using frequentist methods","author":"R\u00fccker","year":"2020"},{"key":"10.1016\/j.genhosppsych.2024.02.008_bb0095","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1016\/j.jclinepi.2010.03.016","article-title":"Graphical methods and numerical summaries for presenting results from multiple-treatment meta-analysis: an overview and tutorial","volume":"64","author":"Salanti","year":"2011","journal-title":"J Clin Epidemiol"},{"key":"10.1016\/j.genhosppsych.2024.02.008_bb0100","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1186\/s12874-015-0060-8","article-title":"Ranking treatments in frequentist network meta-analysis works without resampling methods","volume":"15","author":"R\u00fccker","year":"2015","journal-title":"BMC Med Res Methodol"},{"key":"10.1016\/j.genhosppsych.2024.02.008_bb0105","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1136\/bmj.327.7414.557","article-title":"Measuring inconsistency in meta-analyses","volume":"327","author":"Higgins","year":"2003","journal-title":"BMJ"},{"key":"10.1016\/j.genhosppsych.2024.02.008_bb0110","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/j.jclinepi.2020.04.009","article-title":"In network meta-analysis, most of the information comes from indirect evidence: empirical study","volume":"124","author":"Papakonstantinou","year":"2020","journal-title":"J Clin Epidemiol"},{"key":"10.1016\/j.genhosppsych.2024.02.008_bb0115","doi-asserted-by":"crossref","first-page":"932","DOI":"10.1002\/sim.3767","article-title":"Checking consistency in mixed treatment comparison meta-analysis","volume":"29","author":"Dias","year":"2010","journal-title":"Stat Med"},{"key":"10.1016\/j.genhosppsych.2024.02.008_bb0120","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1002\/jrsm.1044","article-title":"Consistency and inconsistency in network meta-analysis: concepts and models for multi-arm studies","volume":"3","author":"Higgins","year":"2012","journal-title":"Res Synth Methods"},{"key":"10.1016\/j.genhosppsych.2024.02.008_bb0125","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pmed.1003082","article-title":"CINeMA: an approach for assessing confidence in the results of a network meta-analysis","volume":"17","author":"Nikolakopoulou","year":"2020","journal-title":"PLoS Med"},{"key":"10.1016\/j.genhosppsych.2024.02.008_bb0130","article-title":"CINeMA: software for semiautomated assessment of the confidence in the results of network meta-analysis","volume":"16","author":"Papakonstantinou","year":"2020","journal-title":"Campbell Syst Rev"},{"key":"10.1016\/j.genhosppsych.2024.02.008_bb0135","first-page":"12","article-title":"Clozapine and risperidone treatment of psychosis in Parkinson\u2019s disease","author":"Ellis","year":"2000","journal-title":"J Neuropsychiatry Clin Neurosci"},{"key":"10.1016\/j.genhosppsych.2024.02.008_bb0140","first-page":"119","article-title":"Quetiapine improves visual hallucinations in Parkinson disease but not through normalization of sleep architecture: results from a double-blind clinical-polysomnography study","author":"Fernandez","year":"2009","journal-title":"Int J Neurosci"},{"key":"10.1016\/j.genhosppsych.2024.02.008_bb0145","first-page":"55","article-title":"Olanzapine and clozapine: comparative effects on motor function in hallucinating PD patients","author":"Goetz","year":"2000","journal-title":"Neurology"},{"key":"10.1016\/j.genhosppsych.2024.02.008_bb0150","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1097\/WNF.0b013e31824d5115","article-title":"Ziprasidone versus clozapine in the treatment of psychotic symptoms in Parkinson disease: a randomized open clinical trial","volume":"35","author":"Pintor","year":"2012","journal-title":"Clin Neuropharmacol"},{"key":"10.1016\/j.genhosppsych.2024.02.008_bb0155","doi-asserted-by":"crossref","first-page":"150","DOI":"10.12688\/f1000research.2-150.v1","article-title":"A fixed-dose randomized controlled trial of olanzapine for psychosis in Parkinson disease","volume":"2","author":"Nichols","year":"2013","journal-title":"F1000Research"},{"key":"10.1016\/j.genhosppsych.2024.02.008_bb0160","first-page":"52","article-title":"Olanzapine in the treatment of dopamimetic-induced psychosis in patients with Parkinson\u2019s disease","author":"Breier","year":"2002","journal-title":"Biol Psychiatry"},{"key":"10.1016\/j.genhosppsych.2024.02.008_bb0165","first-page":"383","article-title":"Pimavanserin for patients with Parkinson\u2019s disease psychosis: a randomised, placebo-controlled phase 3 trial","author":"Cummings","year":"2014","journal-title":"Lancet (London, England)"},{"key":"10.1016\/j.genhosppsych.2024.02.008_bb0170","doi-asserted-by":"crossref","DOI":"10.1212\/CPJ.0000000000200175","article-title":"Ulotaront, a trace amine-associated receptor 1\/serotonin 5-HT1A agonist, in patients with Parkinson disease psychosis: a pilot study","volume":"13","author":"Isaacson","year":"2023","journal-title":"Neurol Clin Pract"},{"key":"10.1016\/j.genhosppsych.2024.02.008_bb0175","doi-asserted-by":"crossref","first-page":"881","DOI":"10.1038\/npp.2009.176","article-title":"Pimavanserin, a serotonin(2A) receptor inverse agonist, for the treatment of parkinson\u2019s disease psychosis","volume":"35","author":"Meltzer","year":"2010","journal-title":"Neuropsychopharmacol Off Publ Am Coll Neuropsychopharmacol"},{"key":"10.1016\/j.genhosppsych.2024.02.008_bb0180","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1097\/01.WNF.0000236769.31279.19","article-title":"Rater-blinded, prospective comparison: quetiapine versus clozapine for Parkinson\u2019s disease psychosis","volume":"29","author":"Merims","year":"2006","journal-title":"Clin Neuropharmacol"},{"key":"10.1016\/j.genhosppsych.2024.02.008_bb0185","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1097\/01.wnf.0000136891.17006.ec","article-title":"Quetiapine and clozapine in parkinsonian patients with dopaminergic psychosis","volume":"27","author":"Morgante","year":"2004","journal-title":"Clin Neuropharmacol"},{"key":"10.1016\/j.genhosppsych.2024.02.008_bb0190","author":"NCT00125138"},{"key":"10.1016\/j.genhosppsych.2024.02.008_bb0195","author":"NCT00477672"},{"key":"10.1016\/j.genhosppsych.2024.02.008_bb0200","author":"NCT00658567"},{"key":"10.1016\/j.genhosppsych.2024.02.008_bb0205","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.1002\/mds.10217","article-title":"Olanzapine treatment for dopaminergic-induced hallucinations","volume":"17","author":"Ondo","year":"2002","journal-title":"Mov Disord Off J Mov Disord Soc"},{"key":"10.1016\/j.genhosppsych.2024.02.008_bb0210","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1056\/NEJM199903113401003","article-title":"Low-dose clozapine for the treatment of drug-induced psychosis in Parkinson\u2019s disease","volume":"340","author":"Parkinson Study Group","year":"1999","journal-title":"N Engl J Med"},{"key":"10.1016\/j.genhosppsych.2024.02.008_bb0215","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1136\/jnnp.2003.029868","article-title":"Clozapine in drug induced psychosis in Parkinson\u2019s disease: a randomised, placebo controlled study with open follow up","volume":"75","author":"Pollak","year":"2004","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"10.1016\/j.genhosppsych.2024.02.008_bb0220","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1002\/mds.21116","article-title":"Effect of quetiapine in psychotic Parkinson\u2019s disease patients: a double-blind labeled study of 3 months\u2019 duration","volume":"22","author":"Rabey","year":"2007","journal-title":"Mov Disord Off J Mov Disord Soc"},{"key":"10.1016\/j.genhosppsych.2024.02.008_bb0225","doi-asserted-by":"crossref","first-page":"327","DOI":"10.2147\/NDT.S5335","article-title":"A randomized controlled trial of quetiapine for psychosis in Parkinson\u2019s disease","volume":"5","author":"Shotbolt","year":"2009","journal-title":"Neuropsychiatr Dis Treat"},{"key":"10.1016\/j.genhosppsych.2024.02.008_bb0230","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0059202","article-title":"The impact of study size on meta-analyses: examination of underpowered studies in Cochrane reviews","volume":"8","author":"Turner","year":"2013","journal-title":"PloS One"},{"key":"10.1016\/j.genhosppsych.2024.02.008_bb0235","doi-asserted-by":"crossref","first-page":"860","DOI":"10.1016\/j.jclinepi.2015.03.017","article-title":"Small studies are more heterogeneous than large ones: a meta-meta-analysis","volume":"68","author":"IntHout","year":"2015","journal-title":"J Clin Epidemiol"},{"key":"10.1016\/j.genhosppsych.2024.02.008_bb0240","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1002\/mds.27602","article-title":"Update on treatments for nonmotor symptoms of Parkinson\u2019s disease-an evidence-based medicine review","volume":"34","author":"Seppi","year":"2019","journal-title":"Mov Disord Off J Mov Disord Soc"},{"issue":"Suppl. 3","key":"10.1016\/j.genhosppsych.2024.02.008_bb0245","first-page":"S42","article-title":"The movement disorder society evidence-based medicine review update: treatments for the non-motor symptoms of Parkinson\u2019s disease","volume":"26","author":"Seppi","year":"2011","journal-title":"Mov Disord Off J Mov Disord Soc"},{"key":"10.1016\/j.genhosppsych.2024.02.008_bb0250","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1097\/01.wnf.0000164297.91643.ff","article-title":"Use of ziprasidone in parkinsonian patients with psychosis","volume":"28","author":"G\u00f3mez-Esteban","year":"2005","journal-title":"Clin Neuropharmacol"},{"key":"10.1016\/j.genhosppsych.2024.02.008_bb0255","doi-asserted-by":"crossref","DOI":"10.1136\/bmj.f2304","article-title":"Influence of trial sample size on treatment effect estimates: meta-epidemiological study","volume":"346","author":"Dechartres","year":"2013","journal-title":"BMJ"},{"key":"10.1016\/j.genhosppsych.2024.02.008_bb0260","first-page":"80","article-title":"Cholinesterase inhibitors for treatment of psychotic symptoms in Alzheimer disease and Parkinson disease: a meta-analysis","author":"d\u2019Angremont","year":"2023","journal-title":"JAMA Neurol"},{"key":"10.1016\/j.genhosppsych.2024.02.008_bb0265","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1007\/BF02257654","article-title":"Treatment of parkinsonian tremor with clozapine","volume":"2","author":"Fischer","year":"1990","journal-title":"J Neural Transm Park Dis Dement Sect"},{"key":"10.1016\/j.genhosppsych.2024.02.008_bb0270","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1002\/mdc3.12266","article-title":"Clozapine in parkinsonian rest tremor: a review of outcomes, adverse reactions, and possible mechanisms of action","volume":"3","author":"Yaw","year":"2015","journal-title":"Mov Disord Clin Pract"},{"key":"10.1016\/j.genhosppsych.2024.02.008_bb0275","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1192\/bja.2021.24","article-title":"Setting up a clozapine service for Parkinson\u2019s psychosis","volume":"28","author":"Taylor","year":"2022","journal-title":"BJPsych Adv"},{"key":"10.1016\/j.genhosppsych.2024.02.008_bb0280","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.1002\/mdc3.13582","article-title":"Clozapine is severely underused in Parkinson\u2019s disease patients","volume":"9","author":"Friedman","year":"2022","journal-title":"Mov Disord Clin Pract"}],"container-title":["General Hospital Psychiatry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0163834324000380?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0163834324000380?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,27]],"date-time":"2025-09-27T22:56:23Z","timestamp":1759013783000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0163834324000380"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,3]]},"references-count":56,"alternative-id":["S0163834324000380"],"URL":"https:\/\/doi.org\/10.1016\/j.genhosppsych.2024.02.008","relation":{},"ISSN":["0163-8343"],"issn-type":[{"value":"0163-8343","type":"print"}],"subject":[],"published":{"date-parts":[[2024,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Second-generation antipsychotics for Parkinson's disease psychosis: A systematic review and network meta-analysis","name":"articletitle","label":"Article Title"},{"value":"General Hospital Psychiatry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.genhosppsych.2024.02.008","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}